Evidence map›Paper›PMID 40692283›Full record

SynthesisClinical endocrinology2025

Development of a Minimum Dataset for the Global Monitoring of the Safety and Efficacy of Growth Hormone Replacement in Adults With Growth Hormone Deficiency (AGHD).

Suet Ching Chen, Angela K Lucas-Herald, Ruoning Tang, Xanthippi Tseretopoulou, Malika Alimussina, Deno Andrews, Beverly M K Biller, Cesar L Boguszewski, Jillian Bryce, Minglu Chen and 17 more

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Clinical endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Suet Ching ChenDevelopmental Endocrinology Research Group, Royal Hospital for Children, University of Glasgow, Glasgow, UK.ORCID https://orcid.org/0000-0002-2866-6360
Angela K Lucas-HeraldDevelopmental Endocrinology Research Group, Royal Hospital for Children, University of Glasgow, Glasgow, UK.ORCID https://orcid.org/0000-0003-2662-1684
Ruoning TangDevelopmental Endocrinology Research Group, Royal Hospital for Children, University of Glasgow, Glasgow, UK.
Xanthippi TseretopoulouDevelopmental Endocrinology Research Group, Royal Hospital for Children, University of Glasgow, Glasgow, UK.
Malika AlimussinaDevelopmental Endocrinology Research Group, Royal Hospital for Children, University of Glasgow, Glasgow, UK.
Deno AndrewsChicago, Illinois, USA.
Beverly M K BillerNeuroendocrine & Pituitary Tumor Clinical Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
Cesar L BoguszewskiEndocrine Division (SEMPR), Department of Internal Medicine, Federal University of Parana, Curitiba, Brazil.
Jillian BryceOffice for Rare Conditions, University of Glasgow, Glasgow, UK.
Minglu ChenOffice for Rare Conditions, University of Glasgow, Glasgow, UK.
Peter E ClaytonUniversity of Manchester, Manchester, UK.
Maria FleseriuDepartments of Medicine and Neurological Surgery, Pituitary Center, Oregon Health & Science University, Portland, Oregon, USA.ORCID https://orcid.org/0000-0001-9284-6289
Judith GebauerDepartment of Internal Medicine 1, University Hospital of Schleswig-Holstein, Luebeck, Germany.
Ken K Y HoThe Garvan Institute of Medical Research and St. Vincent's Hospital, Sydney, New South Wales, Australia.
Jens Otto L JorgensenAarhus University Hospital, Aarhus, Denmark.
Xiaoping LuoTongji Hospital, Huazhong University of Science and Technology, Wuhan, China.
Bradley S MillerMHealth Fairview Masonic Children's Hospital, University of Minnesota Medical School, Minneapolis, Minnesota, USA.
Sebastian Jcmm NeggersDepartment of Internal Medicine, Section Endocrinology and Pituitary Center, Rotterdam, The Netherlands.
Lars SävendahlDepartment of Women's and Children's Health, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
Katharina SchilbachDepartment of Medicine IV, LMU University Hospital, LMU, Munich, Munich, Germany.
Christian J StrasburgerDepartment of Endocrinology and Metabolic Disorders, Charite Universitaetsmedizin, Berlin, Germany.
Yutaka TakahashiDepartment of Diabetes and Endocrinology, Nara Medical University, Kashihara, Japan.
Diana VitaliSOD ITALY APS Italian Patients Organisation for Septic Optic Dysplasia and Other Neuroendocrine Diseases, Rome, Italy.
Kevin C J YuenBarrow Pituitary Center, University Arizona College of Medicine and Creighton University School of Medicine, Phoenix, Arizona, USA.
Andrew R HoffmanDepartment of Medicine, Stanford University School of Medicine, Stanford, California, USA.
Gudmundur JohannsonSahlgrenska University Hospital and Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
S Faisal AhmedDevelopmental Endocrinology Research Group, Royal Hospital for Children, University of Glasgow, Glasgow, UK.ORCID https://orcid.org/0000-0003-0689-5549

Funding

This study was supported by Chief Scientist Office.
6 · The paper itself

Abstract

objectiveTo identify the minimum dataset (MDS) for the monitoring of safety and effectiveness of GH in adults with growth hormone deficiency (AGHD).

designSystematic review and expert consensus.

methodsOutcomes for AGHD were identified through a systematic literature search in PubMed, Science Direct and Cochrane. In addition, 17 clinical experts from 10 countries and two patient representatives assembled through the Global Registry for Novel Therapies in Rare Bone and Endocrine Conditions (GloBE-Reg) provided data items that ideally should be collected routinely. These items were subsequently graded independently by participants on: (1) importance of the data field and (2) ease of data collection in routine clinical practice.

resultsThe systematic review identified 35 studies with 6732 participants with AGHD with a median age of 49 (range, 22-82) years. The common outcome categories included were cardiovascular in 21 (60%) studies, serum IGF-I in 13 (37%) and IGF-I SDS in 8 (23%), adiposity measures in 15 (44%) and psychosocial outcomes in 10 (29%). A total of 190 items were provided by experts and 86 (45%) achieved sufficient consensus and alignment with reported outcomes to create a final MDS with 45 items to be assessed, of which only 43 are manually entered.

conclusionsThis study has identified by consensus a minimum dataset considered necessary to provide consistency and comparability in global studies of AGHD.

Indexed as

Hormone Replacement TherapyHuman Growth HormoneAdultAgedAged, 80 and overFemaleHumansInsulin-Like Growth Factor IMaleMiddle AgedTreatment OutcomeYoung AdultHuman Growth HormoneInsulin-Like Growth Factor Iadultscore outcomeseffectivenessgrowth hormonegrowth hormone deficiencygrowth hormone replacementsafety

Identifiers

PMID40692283
PMCPMC12583319

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.